ClinicalTrials.gg
Active, not recruitingNCT03584022Updated May 1, 2026

Clinical Trial to Assess the Safety of a Novel Scaffold Biomaterial

An interventional study of Biopsy + Nerve Repair and Biopsy Only in Peripheral Neuropathy, Chronic Inflammatory Demyelinating Polyradiculoneuropathy and Vasculitic Neuropathy (Disorder), sponsored by Mayo Clinic. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-01.

Primary conditionPolyradiculoneuropathy, Chronic Inflammatory DemyelinatingRegistry: Peripheral Nervous System DiseasesReclassifiedWhy we changed it
Registry
Peripheral Nervous System Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Why
  1. The study's listed conditions name Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, a narrower term within Peripheral Nervous System Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Mayo Clinic · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 55 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in United States — 20 open to participants now, 25 under way, 10 of them phase 3. Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States.

Planned enrollment
36th of 42
20 · median 74
Started
2018
the only one that year
No phase
4 of 55
none open now
Primary completion
2027-03
later than 5 of 24 live
Registered
18th of 55
by date

Among the 55 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in United States, this one is the 36th largest by planned enrollment of the 42 interventional ones that give a count, is the only one that started in 2018, is one of 4 with no phase, reaches primary completion later than 5 of the 24 other live ones, and was the 18th registered.

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

137 studies on the registry are indexed under Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; 50 are open to participants now.

Browse Polyradiculoneuropathy, Chronic Inflammatory Demyelinating studies →

Open to participants now

20 of the 55 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 36 Polyradiculoneuropathy, Chronic Inflammatory Demyelinating studies recruiting now, 24 (67%) set no upper age limit and 9 (25%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in United States, or all of them as a file.
02

Study summary

This is safety study. Subjects will be undergoing the surgical procedure of nerve biopsy. After routine surgery without grafting, patients develop swelling, redness, tenderness and dysesthesia at the biopsy site. In order to determine whether grafting is safe compared to not repairing the nerve, it is necessary to compare treated vs. untreated patients using systematic, sensitive and reproducible criteria.

Read the detailed description

Patients will be evaluated for eligibility and then, after gaining informed consent, the surgical procedure will be scheduled. Baseline evaluations include physical/neurological examination, nerve conduction study and ultrasonography of the sural nerve, and testing for erythrocyte sedimentation rate, C-reactive protein and complete blood counts (with white blood cell differential). Surgery is done in an operating room under local or monitored anesthesia, depending on patient preference. An incision will be made above the ankle. Immediately after the surgery, the patient will repeat the baseline physical/neurological exams, and sural nerve ultrasonography.

Participants will be evaluated either in the clinic or by phone on a regular basis and will be required to keep a journal and fill out symptom questionnaires for up to 12 months post-procedure.

Development of a grade 4 local reaction at any time will fulfill criteria for review by the Data and Safety Monitoring Board (DSMB) for implant removal and definition as a failure.

03

Conditions studied

  • Peripheral Neuropathy
  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy
  • Vasculitic Neuropathy (Disorder)
  • Amyloidosis
  • Hereditary Neuropathy
  • Sarcoid Neuropathy
04

In context

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Reclassified

137 studies on the registry are indexed under Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; 50 are open to participants now.

This study's planned enrollment of 20 is below the median of 39 across 84 interventional studies indexed under Polyradiculoneuropathy, Chronic Inflammatory Demyelinating.

Browse Polyradiculoneuropathy, Chronic Inflammatory Demyelinating studies →

Lead sponsor

Mayo Clinic is the lead sponsor of 3,272 studies on the registry; 672 are open to participants now.

Of its 452 completed or terminated interventional studies of FDA-regulated products, 322 (71%) have results posted.

Compared within Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Peripheral Nervous System Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are between the ages of 18-75 years
  • Have clinical indications for whole sural nerve
  • Have a sural nerve SNAP with amplitude > or = 2 microvolt (μV)
  • Are able to comply with protocol requirements
  • Can provide written
  • Willingness to complete study procedures

Exclusion criteria

Exclusion Criteria

  • Current smoker.
  • History of prior musculoskeletal (joint or soft tissue) infection.
  • Pre-operative nares culture positive for methicillin-resistant Staphylococcus Aureus (MRSA) or methicillin-sensitive Staphylococcus Aureus (MSSA)
  • Have systemic immune disorders, such as Crohn's Disease, rheumatoid arthritis, or psoriasis with the exception of hyper/hypothyroidism.
  • Have diabetes mellitus.
  • Have previous trauma to the site.
  • Have any major, medical condition (e.g., within six months of baseline, had myocardial infarction, angina pectoris, and/or congestive heart failure) that, in the opinion of the investigator, would compromise the safety of patient.
  • Are pregnant or breast-feeding.
  • Unwilling to use adequate .
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

06

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Biopsy + Nerve Repair

    Subjects will undergo standard sural nerve biopsy plus repair of the 6 cm nerve defect using a synthetic polymer (PCLF) nerve tube.

    Device: Biopsy + Nerve Repair

  • Sham comparator
    Biopsy Only

    Subjects will undergo the same standard sural nerve biopsy procedure as the Experimental Group, but will not include the nerve repair.

    Procedure: Biopsy Only

Interventions

  • DeviceBiopsy + Nerve Repair

    During the standard sural nerve biopsy procedure, a single-use, biodegradable implant designed to repair damaged peripheral nerves will be used to repair the nerve. The MCNS1 is a hollow nerve tube made of poly(caprolactone-fumarate) (PCLF), to connect severed nerve ends and promote the growth of regenerating axons.

  • ProcedureBiopsy Only

    Standard sural nerve biopsy only, without nerve repair.

07

What researchers measure

Primary outcomes

  1. Safety as determined by number of participants with post-surgical reactions

    Post-surgical reactions will include evaluations of the following: 1. Percussion tenderness at site of proximal stump or repair site; 2. Skin redness at the site of biopsy (length and width measured with calipers); 3. Development of mild or moderate swelling along the site (yes or no). It is anticipated that this will resolve to a lower grade or progress to grade 4. 4. Development of severe swelling or pustules or evidence of tube extrusion or wound dehiscence.

    Time frame: up to 5 years post surgery

Secondary outcomes

  1. Neuropathic pain as measured by SNAP

    Sensory nerve action potential (SNAP) will be measured at the ankle using small electric shocks and recording pads on the skin. This will be done by an experienced and board-certified electrophysiologist.

    Time frame: 3 months & 12 months

  2. Neuropathic pain as measured by visual analogue pain scale

    The Visual Analogue Scale (VAS) consists of a straight line with the endpoints of 'No pain' and 'Pain as bad as it could possibly be'. The subject is asked to mark his or her pain level on the line between the two endpoints. The distance between 'no pain at all' and the mark defines the subject's pain.

    Time frame: weekly, monthly for first 3 months, then 12 months and yearly for 4 years

  3. Neuropathic pain as measured by visual analogue pain assessment questionnaire

    Subjects will be asked to check all of the following that apply: 1) fever, 2) unexplained or new joint aches and pain, 3) increased skin redness at or near the site of the biopsy, 4) increased swelling at or near the site of the biopsy, 5) some degree of pain or discomfort at or near the site of the biopsy

    Time frame: weekly, monthly for first 3 months, then 12 months and yearly for 4 years

  4. Neuroma formation

    Non-invasive nerve ultrasound will be performed to determine neuroma formation

    Time frame: 3 months & 12 months

  5. Sensory nerve regeneration as measured by SNAP

    The amplitude of sensory nerve action potential (SNAP) will be used to determine sensory nerve regeneration

    Time frame: 3 months & 12 months

  6. Sensory nerve regeneration as measured by ultrasound

    Non-invasive nerve ultrasound will be performed to determine sensory nerve regeneration

    Time frame: 3 months & 12 months

08

Study locations

1 site
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2018 (actual). Primary completion is estimated for Mar 2027, 100 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2018
First posted
Jul 12, 2018
StartActual
Nov 9, 2018
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03584022
Lead sponsor
Mayo Clinic
Responsible party
Anthony J. Windebank (Professor of Neurology, Mayo Clinic) — Principal investigator
First posted
Jul 12, 2018
Start date
Nov 9, 2018
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
May 1, 2026

Study contacts

Anthony J Windebank, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion